Literature DB >> 6121303

Low cerebrospinal fluid somatostatin in Parkinson disease: an irreversible abnormality.

E Dupont, S E Christensen, A P Hansen, B de Fine Olivarius, H Orskov.   

Abstract

In 39 parkinsonian patients, CSF somatostatin content was 88.0 +/- 4.1 pg per milliliter, which was about 40% less than in controls (147.3 +/- 5.1 pg per milliliter). Somatostatin values were unrelated to age, sex, body weight, total CSF protein, immunoglobulin, or cell count in either group. Parkinsonian values were not related to duration of disease, severity, specific signs, or treatment. In contrast to multiple sclerosis, in which CSF somatostatin is low only during relapses, the low somatostatin content of CSF in Parkinson disease seems to be irreversible, to be present at the onset of symptoms, and to imply an irreparable functional or structural alteration of somatostatin-secreting neurons.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6121303     DOI: 10.1212/wnl.32.3.312

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  20 in total

1.  CSF somatostatin-like immunoreactivity in dementia of Parkinson's disease.

Authors:  W Poewe; T Benke; E Karamat; L Schelosky; M Wagner; G Sperk
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-12       Impact factor: 10.154

Review 2.  Alterations in neuropeptides in aging and disease. Pathophysiology and potential for clinical intervention.

Authors:  A Leake; I N Ferrier
Journal:  Drugs Aging       Date:  1993 Sep-Oct       Impact factor: 3.923

3.  Decrease in somatostatin-positive cell density in the amygdala of females with major depression.

Authors:  Gaelle Douillard-Guilloux; David Lewis; Marianne L Seney; Etienne Sibille
Journal:  Depress Anxiety       Date:  2016-08-24       Impact factor: 6.505

4.  Ventricular somatostatin-like immunoreactivity in patients with basal ganglia disease.

Authors:  H Cramer; A Wolf; K Rissler; K Weigel; C Ostertag
Journal:  J Neurol       Date:  1985       Impact factor: 4.849

5.  Somatostatin-like immunoreactivity, its molecular forms and monoaminergic metabolites in aged and demented patients with Parkinson's disease--effect of L-Dopa.

Authors:  M Strittmatter; G F Hamann; D Strubel; H Cramer; K Schimrigk
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

6.  Somatostatin-like immunoreactivity and substance-P-like immunoreactivity in the CSF of patients with senile dementia of Alzheimer type, multi-infarct syndrome and communicating hydrocephalus.

Authors:  H Cramer; D Schaudt; K Rissler; D Strubel; J M Warter; F Kuntzmann
Journal:  J Neurol       Date:  1985       Impact factor: 4.849

7.  Lack of effect of chronic carbamazepine on brain somatostatin in the rat.

Authors:  S R Weiss; T Nguyen; D R Rubinow; C J Helke; P K Narang; R M Post; D M Jacobowitz
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

Review 8.  The hypothalamus in Parkinson disease.

Authors:  R Sandyk; R P Iacono; C R Bamford
Journal:  Ital J Neurol Sci       Date:  1987-06

9.  Predator stress induces behavioral inhibition and amygdala somatostatin receptor 2 gene expression.

Authors:  S A Nanda; C Qi; P H Roseboom; N H Kalin
Journal:  Genes Brain Behav       Date:  2008-03-21       Impact factor: 3.449

Review 10.  Neuropeptides in dopamine-containing regions of the brain.

Authors:  A Albanese; M C Altavista
Journal:  Ital J Neurol Sci       Date:  1984-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.